New Delhi, June 14, 2021: Wellthy Therapeutics, a leading digital therapeutics (DTx) company operating in Europe and Asia, recently conducted a 16-week real world study, to test the real-world effectiveness, efficacy and remote patient monitoring and management capabilities of its Wellthy CARE ™ DTx platform. The platform consists of a clinical and behavioural intelligence engine, delivering care through a mobile app, paramedical dashboards, HCP dashboards and enterprise analytics. In this study, a clinically validated Type 2 Diabetes Digital Therapy was delivered through the Wellthy CARE ™ DTx platform, to evaluate glycemic control in Type 2 Diabetes Mellitus (T2DM) patients of South Asian origin. The findings were published in the Journal of Medical Internet Research (JMIR) as a full text publication.
The Study, ‘Evaluating Glycemic Control in Patients of South Asian Origin with T2DM Using a Digital Therapeutic Platform: Analysis of Real-World Data’, tracked and analyzed 102 patients with T2DM from India, enrolled in a 16-week structured self-management program which was delivered 100% via the Wellthy CARE™ DTx platform. Average change observed in HBA1c was -0.49%. Patients with the highest engagement showed a reduction in HbA1c by 0.84%, fasting blood glucose (FBG) by 11 mg/dl, post-prandial blood glucose (PPBG) by 21 mg/dl, weight by 1.32 kg and BMI by 0.47 kg/m2.. The study program was based on the American Association of Diabetes Educators AADE7 self-care behaviors and works on the model of digital persuasion while providing culturally relevant content and nudges. The study demonstrated significant improvements in real world outcomes, achieved via a Digital Therapeutic intervention delivered using the Wellthy CARE™ DTx platform.
T2DM has been growing fast among South Asians with the number of patients projected to grow from 88 million in 2019 to 115 million in 2030.The health infrastructure and the existing standard of care have created a wider gap between the real-world patient outcomes, and guideline approved, personalised care, that is recommended for patients with chronic diseases like T2DM.
Combating this challenge of unmet medical needs, during the study, patients received clinically validated guidance on self-care behaviors and adherence via a chatbot and certified Diabetes educators, along with remote monitoring, protocol driven care and continuous personalised feedback on their patient reported data, all powered by the Wellthy CARE™ DTx platform. Health care professionals received clinical decision support both real time and episodically.
Dr Banshi Saboo, Chief Diabetologist and Chairman Diabetes Care “The need for innovative clinically validated solutions as Wellthy Care’s DTx, with self-monitoring tools like self-monitoring of Blood Glucose (SMBG), FBG etc is a powerful combination to improve patient engagement and improve patient outcomes. The key findings of this peer reviewed publication were positive improvements in glucose outcomes in the real world and confirming the potential of Digital Therapeutics in better management of Diabetes. I am hopeful that in the future the adoption of Digital Therapeutics would grow and we would be able to scale precision healthcare.”
Speaking on the study, Dr Sid Kolwankar, AVP- Clinical and Product, Wellthy Therapeutics, said, “At Wellthy Therapeutics, we continue to push the boundaries of evidence-based, real world medicine, with the patient at the centre. This study further demonstrates the capability of the Wellthy CARE™ Platform to power clinically validated, condition specific, digital therapies to achieve real world outcomes in resource constrained settings. These findings validate the role of digital therapeutics in the standard of care for chronic conditions.”
Link to the study: https://www.jmir.org/2021/3/e17908/
Corporate Comm India (CCI Newswire)
